IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.546
EU - Europa 1.253
AS - Asia 694
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 3.521
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.521
CN - Cina 370
SE - Svezia 290
IE - Irlanda 289
IT - Italia 272
SG - Singapore 228
DE - Germania 109
TR - Turchia 68
FI - Finlandia 63
FR - Francia 55
AT - Austria 51
CA - Canada 24
GB - Regno Unito 22
CZ - Repubblica Ceca 21
RO - Romania 20
BE - Belgio 16
CI - Costa d'Avorio 16
IN - India 16
NL - Olanda 10
UA - Ucraina 7
EU - Europa 6
LT - Lituania 6
ES - Italia 5
RU - Federazione Russa 4
BG - Bulgaria 3
IR - Iran 3
LU - Lussemburgo 3
SC - Seychelles 3
IL - Israele 2
KH - Cambogia 2
NG - Nigeria 2
SM - San Marino 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
HK - Hong Kong 1
JP - Giappone 1
MD - Moldavia 1
PH - Filippine 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.521
Salva come PNG Salva come JPEG
Città #
Chandler 333
Dublin 286
Singapore 185
Santa Clara 175
Parma 119
Ashburn 115
Ann Arbor 93
Shanghai 90
Boardman 71
Dearborn 67
New York 57
Izmir 54
Nanjing 51
Vienna 51
Beijing 46
Princeton 45
Marseille 37
Helsinki 28
Wilmington 27
Bremen 23
Munich 23
Shenyang 23
Los Angeles 21
Brno 18
Abidjan 16
Brussels 16
San Mateo 15
Toronto 15
Hebei 14
Kunming 14
Jinan 13
Nanchang 13
Kocaeli 12
Milan 12
Focsani 10
Modena 10
Redmond 10
Bologna 8
Changsha 8
Fairfield 8
Houston 8
Jiaxing 8
Woodbridge 8
Guangzhou 7
Hefei 7
London 7
Norwalk 7
Dallas 6
Pune 6
Savignano sul Rubicone 6
Tianjin 6
Washington 6
Zhengzhou 6
Des Moines 5
Düsseldorf 5
Frankfurt am Main 5
Hangzhou 5
Jacksonville 5
Madrid 5
Ottawa 5
Palermo 5
Rho 5
Rome 5
Seattle 5
Rio Saliceto 4
Romainville 4
Torino 4
Ahmedabad 3
Cesena 3
Fremont 3
Gorgonzola 3
Lviv 3
Nürnberg 3
Redwood City 3
Reggio Emilia 3
San Giuliano Milanese 3
Sofia 3
St Louis 3
Wuhan 3
Amsterdam 2
Arcevia 2
Borås 2
Cento 2
Chengdu 2
Cornaredo 2
Deiva Marina 2
Edinburgh 2
Florence 2
Grafing 2
Harbin 2
Lagos 2
Luxembourg 2
Manchester 2
Medesano 2
Montreal 2
Paris 2
Phnom Penh 2
Piacenza 2
Pilastro 2
Sabz 2
Totale 2.465
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 111
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 106
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 105
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 94
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 93
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 92
Novel targets for the treatment of relapsing multiple myeloma 91
Possible targets to treat myeloma-related osteoclastogenesis 88
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 87
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 87
Oncolytic virotherapy and microenvironment in multiple myeloma 86
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 84
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 84
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 84
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 83
A simplified sars-cov-2 pseudovirus neutralization assay 82
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 81
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 79
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 79
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 78
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 77
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 76
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 75
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 75
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 74
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 72
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 72
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 71
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 70
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 70
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 70
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 66
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 65
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 65
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 65
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 64
Role of Galectins in Multiple Myeloma. 61
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 60
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 58
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 58
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 57
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 55
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 54
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 53
The impact of CD56 expression in smoldering myeloma patients on early progression 49
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 46
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 39
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 34
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 33
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 29
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 26
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 19
Totale 3.632
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.728
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.728
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020188 0 0 0 0 0 58 46 8 24 36 10 6
2020/2021250 30 4 7 7 40 8 15 22 44 28 16 29
2021/2022296 6 10 10 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/2025613 27 60 84 140 162 140 0 0 0 0 0 0
Totale 3.632